Sanofi's amlitelimab succeeds in Phase 3 atopic dermatitis study
Ticker: SNYNF · Form: 6-K · Filed: Sep 4, 2025 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | Sep 4, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial-results, pharmaceuticals, atopic-dermatitis
TL;DR
Sanofi's amlitelimab crushed Phase 3 trials for eczema, big news for skin disease treatment!
AI Summary
On September 4, 2025, Sanofi announced that its drug amlitelimab successfully met all primary and key secondary endpoints in the COAST 1 Phase 3 study for treating atopic dermatitis in adults and adolescents. This positive outcome suggests potential for a new treatment option for patients suffering from this chronic skin condition.
Why It Matters
Positive Phase 3 results for amlitelimab could lead to a new treatment option for atopic dermatitis, potentially impacting the market for dermatological therapies.
Risk Assessment
Risk Level: low — This filing is a routine report of a press release announcing positive clinical trial results, with no immediate financial or operational risks indicated.
Key Players & Entities
- Sanofi (company) — Registrant and developer of amlitelimab
- amlitelimab (drug) — Drug candidate tested in the study
- COAST 1 (study) — Name of the Phase 3 clinical trial
- September 4, 2025 (date) — Date of the press release
FAQ
What specific endpoints did amlitelimab meet in the COAST 1 study?
Amlitelimab met all primary and key secondary endpoints in the COAST 1 Phase 3 study.
What condition is amlitelimab being studied for?
Amlitelimab is being studied for the treatment of atopic dermatitis.
What was the patient population for the COAST 1 study?
The COAST 1 study included adults and adolescents with atopic dermatitis.
What type of study was the COAST 1 trial?
The COAST 1 trial was a Phase 3 study.
When was the press release regarding the study results published?
The press release was published on September 4, 2025.
Filing Stats: 193 words · 1 min read · ~1 pages · Grade level 13.6 · Accepted 2025-09-04 12:55:00
Filing Documents
- d32034d6k.htm (6-K) — 8KB
- d32034dex991.htm (EX-99.1) — 35KB
- g32034g04g02.jpg (GRAPHIC) — 2KB
- g32034g04g04.jpg (GRAPHIC) — 4KB
- g32034g05g05.jpg (GRAPHIC) — 43KB
- 0001193125-25-195777.txt ( ) — 112KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: September 4, 2025 SANOFI By /s/ Alexandra Roger Name: Alexandra Roger Title: Head of Legal Corporate & Finance 3